Skip to main content
SpringerLink
Log in

Mucosal Melanoma: Epidemiology, Biology and Treatment

  • Chapter
  • First Online:
Melanoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 167))

Abstract

Mucosal melanoma is an exceedingly rare variant of cutaneous melanoma that, due to its rarity, is poorly described and infrequently studied. Primary sites of origin include the head and neck, anorectum and vulvovaginal regions. It is uniquely different from cutaneous melanoma with respect to epidemiology, etiology, pathogenesis and prognosis. The etiology and pathogenesis remain unclear. Unlike cutaneous melanoma, exposure to UV light is not an apparent risk factor. Furthermore, distinct molecular features including a lower incidence of BRAF oncogene mutations but a higher incidence of KIT oncogene mutations suggest divergent genetic etiologies. Mucosal melanomas generally present at a later stage, are more aggressive and carry a worse prognosis regardless of the stage at diagnosis. Establishing standardized treatment guidelines has been challenging due to the rarity of the disease. Early detection provides the best chance at survival but is often difficult due to anatomic location. Surgery remains the primary therapeutic intervention if complete resection is technically feasible given the anatomic location. Radiotherapy may be used to achieve local control when resection is not feasible, or adjuvantly to enhance locoregional control, but most studies have failed to demonstrate an improvement in overall survival. There are no consensus guidelines on the optimal systemic therapy, and regimens are often extrapolated from data based on therapies used to treat advanced cutaneous melanoma. Clinical trials, particularly utilizing newer targeted therapies and immunotherapies, are investigating novel treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31(26):3205–3211. doi:10.1200/JCO.2013.49.8691

    Article  CAS  PubMed  Google Scholar 

  2. Ballantyne AJ (1970) Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 120(4):425–431

    Article  CAS  PubMed  Google Scholar 

  3. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB (2008) Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592–1598. doi:10.1002/hed.20910

    Article  PubMed  Google Scholar 

  4. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14(21):6821–6828. doi:10.1158/1078-0432.CCR-08-0575

    Article  CAS  PubMed  Google Scholar 

  5. Borazjani G, Prem KA, Okagaki T, Twiggs LB, Adcock LL (1990) Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases. Gynecol Oncol 37(2):264–267

    Article  CAS  PubMed  Google Scholar 

  6. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13(6):589–597. doi:10.1016/S1470-2045(12)70138-9

    Article  PubMed  Google Scholar 

  7. Carcoforo P, Raiji MT, Palini GM, Pedriali M, Maestroni U, Soliani G, Detroia A, Zanzi MV, Manna AL, Crompton JG, Langan RC, Stojadinovic A, Avital I (2012) Primary anorectal melanoma: an update. J Cancer 3:449–453. doi:10.7150/jca.5187

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305(22):2327–2334. doi:10.1001/jama.2011.746

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Carvajal RD, Spencer SA, Lydiatt W (2012) Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Cancer Netw JNCCN 10(3):345–356

    CAS  PubMed  Google Scholar 

  10. Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83(8):1664–1678

    Article  CAS  PubMed  Google Scholar 

  11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/NEJMoa1103782

  12. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340–4346. doi:10.1200/JCO.2006.06.2984

    Article  CAS  PubMed  Google Scholar 

  13. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabro L, Maio M (2014) Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 50(1):121–127. doi:10.1016/j.ejca.2013.09.007

    Article  PubMed  Google Scholar 

  14. DeMatos P, Tyler DS, Seigler HF (1998) Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 5(8):733–742

    Article  CAS  PubMed  Google Scholar 

  15. Dummer R, Daud A, Puzanov I, Hamid O, Schadendorf D, Robert C, Schachter J, Pavlick A, Gonzalez R, Hodi F, Cranmer L, Blank C, O’Day S, Ascierto P, Salama A, Li NX, Zhou W, Lis J, Ebbinghaus S, Kang P, Ribas A (2015) A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. Journal of Translational Medicine 13(Suppl 1):O5

    Article  PubMed Central  Google Scholar 

  16. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. doi:10.1245/s10434-010-0985-4

    Article  PubMed  Google Scholar 

  17. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, Ramirez PT (2010) Primary malignant melanoma of the vagina. Obstet Gynecol 116(6):1358–1365. doi:10.1097/AOG.0b013e3181fb8045

    Article  PubMed  Google Scholar 

  18. Gilligan D, Slevin NJ (1991) Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 64(768):1147–1150

    Article  CAS  PubMed  Google Scholar 

  19. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29(21):2904–2909. doi:10.1200/JCO.2010.33.9275

    Article  CAS  PubMed  Google Scholar 

  20. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144. doi:10.1056/NEJMoa1305133

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Hardie C, Siddiqui N (2011) Primary Malignant Melanoma of the Vulva and Vagina. In: Reed N, Green JA, Gershenson DM, Siddiqui N, Connor R (eds) Rare and uncommon gynecologic cancers. Springer, New York

    Google Scholar 

  22. Harting MS, Kim KB (2004) Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 14(6):517–520

    Article  CAS  PubMed  Google Scholar 

  23. Harwood AR, Cummings BJ (1982) Radiotherapy for mucosal melanomas. Int J Radiat Oncol Biol Phys 8(7):1121–1126

    Article  CAS  PubMed  Google Scholar 

  24. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26(12):2046–2051. doi:10.1200/JCO.2007.14.0707

    Article  CAS  PubMed  Google Scholar 

  25. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O’Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31(26):3182–3190. doi:10.1200/JCO.2012.47.7836

    Article  CAS  PubMed  Google Scholar 

  27. Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG, Cancer, Aging Research G (2014) Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. Journal Clin Oncol 32 (24):2587–2594. doi:10.1200/JCO.2013.55.0418

    Google Scholar 

  28. Hussein MR (2008) Extracutaneous malignant melanomas. Cancer Invest 26(5):516–534. doi:10.1080/07357900701781762

    Article  PubMed  Google Scholar 

  29. Keller DS, Thomay AA, Gaughan J, Olszanski A, Wu H, Berger AC, Farma JM (2013) Outcomes in patients with mucosal melanomas. J Surg Oncol 108(8):516–520. doi:10.1002/jso.23445

    Article  PubMed  Google Scholar 

  30. Kelly P, Zagars GK, Cormier JN, Ross MI, Guadagnolo BA (2011) Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer 117(20):4747–4755. doi:10.1002/cncr.26088

    Article  PubMed  Google Scholar 

  31. Kim HS, Kim EK, Jun HJ, Oh SY, Park KW, Lim do H, Lee SI, Kim JH, Kim KM, Lee DH, Lee J (2010) Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer 10:167. doi:10.1186/1471-2407-10-167

  32. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY (2004) Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100(7):1478–1483. doi:10.1002/cncr.20113

    Article  CAS  PubMed  Google Scholar 

  33. Kirschner AN, Kidd EA, Dewees T, Perkins SM (2013) Treatment approach and outcomes of vaginal melanoma. International J Gynecol Cancer 23(8):1484–1489. doi:10.1097/IGC.0b013e3182a1ced8

    Article  Google Scholar 

  34. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876. doi:10.1056/NEJMoa1408868

    Article  PubMed  Google Scholar 

  35. Leitao MM Jr (2014) Management of vulvar and vaginal melanomas: current and future strategies. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting e277–281. doi:10.14694/EdBook_AM.2014.34.e277

    Google Scholar 

  36. Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, Li S, Kong Y, Tang B, Guo J (2013) Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 19(16):4488–4498. doi:10.1158/1078-0432.CCR-13-0739

    Article  CAS  PubMed  Google Scholar 

  37. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888. doi:10.1056/NEJMoa1406037

    Article  PubMed  Google Scholar 

  38. Lourenco SV, Fernandes JD, Hsieh R, Coutinho-Camillo CM, Bologna S, Sangueza M, Nico MM (2014) Head and neck mucosal melanoma: a review. Am J Dermatopathol 36(7):578–587. doi:10.1097/DAD.0000000000000035

    Article  PubMed  Google Scholar 

  39. Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigm Cell Melanoma Res 21(4):492–493. doi:10.1111/j.1755-148X.2008.00475.x

    Article  Google Scholar 

  40. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489. doi:10.1038/nature10673

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V (2012) Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 5(8):739–753

    PubMed Central  PubMed  Google Scholar 

  42. Min L, Hodi FS (2014) Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2(1):15–18. doi:10.1158/2326-6066.CIR-13-0146

    Article  PubMed Central  PubMed  Google Scholar 

  43. Moreno MA, Roberts DB, Kupferman ME, DeMonte F, El-Naggar AK, Williams M, Rosenthal DS, Hanna EY (2010) Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M.D. Anderson Cancer Center. Cancer 116(9):2215–2223. doi:10.1002/cncr.24976

    PubMed  Google Scholar 

  44. Nieder C (2012) Ipilimumab in patients with melanoma and brain metastases. Lancet Oncol 13(7):e277; author reply e277–278. doi:10.1016/S1470-2045(12)70303-0

    Google Scholar 

  45. Pandey M, Mathew A, Abraham EK, Ahamed IM, Nair KM (1998) Primary malignant melanoma of the mucous membranes. European J Surg Oncol 24(4):303–307

    Article  CAS  Google Scholar 

  46. Patrick RJ, Fenske NA, Messina JL (2007) Primary mucosal melanoma. J Am Acad Dermatol 56(5):828–834. doi:10.1016/j.jaad.2006.06.017

    Article  PubMed  Google Scholar 

  47. Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf G, Worden F, National Comprehensive Cancer N (2012) Mucosal melanoma of the head and neck. J Natl Compr Cancer Network JNCCN 10(3):320–338

    PubMed  Google Scholar 

  48. Postow MA, Hamid O, Carvajal RD (2012) Mucosal melanoma: pathogenesis, clinical behavior, and management. Curr Oncol Rep 14(5):441–448. doi:10.1007/s11912-012-0244-x

    Article  CAS  PubMed  Google Scholar 

  49. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D’Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD (2013) Ipilimumab for patients with advanced mucosal melanoma. Oncologist 18(6):726–732. doi:10.1634/theoncologist.2012-0464

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P (2008) Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737–740. doi:10.1038/ncponc1251

    Article  CAS  PubMed  Google Scholar 

  51. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526. doi:10.1056/NEJMoa1104621

    Article  CAS  PubMed  Google Scholar 

  52. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39. doi:10.1056/NEJMoa1412690

    Article  PubMed  Google Scholar 

  53. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. doi:10.1056/NEJMoa1412082

    Article  CAS  PubMed  Google Scholar 

  54. Seetharamu N, Ott PA, Pavlick AC (2010) Mucosal melanomas: a case-based review of the literature. Oncologist 15(7):772–781. doi:10.1634/theoncologist.2010-0067

    Article  PubMed Central  PubMed  Google Scholar 

  55. Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD (2011) Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol 29(33):e809–811. doi:10.1200/JCO.2011.36.8829

    Article  PubMed  Google Scholar 

  56. Tas F, Keskin S, Karadeniz A, Dagoglu N, Sen F, Kilic L, Yildiz I (2011) Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology 81(5–6):353–358. doi:10.1159/000334863

    Article  PubMed  Google Scholar 

  57. Tomicic J, Wanebo HJ (2003) Mucosal melanomas. Surg Clin North Am 83(2):237–252. doi:10.1016/S0039-6109(02)00100-7

    Article  PubMed  Google Scholar 

  58. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. doi:10.1200/JCO.2013.53.0105

    Article  CAS  PubMed  Google Scholar 

  59. Verschraegen CF, Benjapibal M, Supakarapongkul W, Levy LB, Ross M, Atkinson EN, Bodurka-Bevers D, Kavanagh JJ, Kudelka AP, Legha SS (2001) Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 11(5):359–364

    Google Scholar 

  60. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. New Engl J Med 369(2):122–133. doi:10.1056/NEJMoa1302369

    Article  CAS  PubMed  Google Scholar 

  61. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA (2009) Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079–2085. doi:10.1158/1535-7163.MCT-09-0459

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Woodman SE, Davies MA (2010) Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568–574. doi:10.1016/j.bcp.2010.04.032

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Wu E, Golitz LE (2000) Primary noncutaneous melanoma. Clinics Lab Med 20(4):731–744

    CAS  Google Scholar 

  64. Zhu YSL, Kong Y, Chi Z, Yuan X, Cui C, Sheng X, Guo J, Shen L (2009) Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 27(15s):e20017

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA

    Kristen R. Spencer & Janice M. Mehnert

Authors
  1. Kristen R. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janice M. Mehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristen R. Spencer .

Editor information

Editors and Affiliations

  1. Rutgers Cancer Institute of New Jersey, New Brunswick, New York, USA

    Howard L. Kaufman

  2. Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA

    Janice M. Mehnert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Spencer, K.R., Mehnert, J.M. (2016). Mucosal Melanoma: Epidemiology, Biology and Treatment. In: Kaufman, H., Mehnert, J. (eds) Melanoma. Cancer Treatment and Research, vol 167. Springer, Cham. https://doi.org/10.1007/978-3-319-22539-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22539-5_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22538-8

  • Online ISBN: 978-3-319-22539-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation